We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Roche to Develop New Diagnostic Technologies for Traumatic Brain Injuries

By LabMedica International staff writers
Posted on 14 Oct 2024

Traumatic brain injuries (TBI) represent a significant global health issue, affecting approximately 69 million people each year. More...

TBI occurs when an external force disrupts normal brain function, with severity ranging from mild (such as concussions) to moderate and severe forms. The effects of TBI can be long-lasting, potentially resulting in permanent disabilities. Individuals who suffer from TBI may experience a range of symptoms, including cognitive impairments, motor difficulties, emotional disturbances, and behavioral changes. The broader impact of TBI is felt not only by the patients themselves but also by their families, healthcare systems, and society, highlighting the need for improved management, support structures, and collaborative efforts to enhance patient outcomes. Unfortunately, studies indicate that TBI is often underdiagnosed or diagnosed too late, underscoring the need for quicker and more accurate diagnostic methods to facilitate timely and effective treatment.

To address these challenges, Roche Diagnostics (Basel, Switzerland) has entered into a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) Burn and Blast Medical Countermeasures Program to drive innovation in TBI diagnosis. Through this collaboration, Roche and BARDA aim to develop novel diagnostic technologies that address the widespread impact of TBI, as well as enhance healthcare system preparedness for mass casualty events. Currently, neuroimaging techniques like CT and MRI scans are the primary diagnostic tools for TBI, but these methods can be costly and may not be widely available in mass casualty scenarios. Additionally, neuroimaging alone is insufficient for diagnosing all types of TBI and predicting patient outcomes.

A major challenge lies in accurately stratifying patients with mild TBI to determine whether they require immediate intervention, further observation, or follow-up. A potential solution could be the development of a blood-based test, combined with clinical, physiological, or imaging data, to help healthcare professionals quickly identify and categorize TBI patients. Such a tool would enable earlier interventions, help prevent lasting damage, and improve the ability to predict patient outcomes and monitor treatment effectiveness. The goal of this partnership is to bring these innovations to market, potentially revolutionizing the way TBI is diagnosed and treated.

“We are honored to collaborate with BARDA on this important initiative,” said Life Cycle Leader Cardiometabolic and Neurology, Roche Diagnostics. “Our goal is to drive meaningful advancements in healthcare, ultimately enhancing patient care, outcomes and access. This partnership underscores our commitment to advancing medical diagnostics and addressing critical healthcare challenges such as scalable and accurate testing for traumatic brain injuries.

Related Links:
Roche Diagnostics


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR System
OnePCR
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more

Pathology

view channel
Image: The Aiforia Breast Cancer Grading AI solution is CE-IVD marked (Photo courtesy of Aiforia Technologies)

Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy

Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.